E22505 Background: Leiomyosarcoma of bone (LMSoB) is a rare malignant bone tumor. Its clinical outcome has not been deeply assessed in the literature. This multicenter retrospective study was conducted to investigate the diagnosis and the clinical outcome of primary LMSoB in Japan. Methods: Forty-eight patients (average age: 52 years [range 14-88 years]) with primary LMSoB who were treated at registered institutes in Japan between 1991 and 2014 were recruited. The median follow-up period was 44 months (range: 2-273). Results: The 5-year overall survival rates and disease-free survival rates were 78.3% and 44.9% respectively. Surgical treatment was performed in 42 patients (87.5%), and an adequate safe margin (R0 resection) was achieved in 31 patients (73.8%). Neoadjuvant chemotherapy was administered in 18 patients. The most common regimen (cisplatin-based chemotherapy) was administered in 15 patients (83.3%), but no patient achieved a good response in both radiological and histological evaluation. The presence of metastasis at the first visit and a lack of definitive surgery were significantly correlated with poor overall survival (p = 0.0036 and p = 0.0355, respectively), and the surgical margin was a significant prognostic factor for disease-free survival (p = 0.0005). Conclusions: The present study reveals the clinical outcomes and treatments in the largest case series ever reported for LMSoB. Surgical treatment with wide margins was the only treatment that proved to be effective, whereas adjuvant chemotherapy did not improve the overall survival. The results underscore the need to seek a novel chemotherapy regimen and alternative chemotherapy regimens that are effective for leiomyosarcoma arising from other tissues need to be tested for LMSoB.